In the United Kingdom, the Clinical Practice Research Datalink (CPRD) national registry, comprising primary care data from almost 3 million patient electronic health record (EHR), has been shown to have good external validity for estimating the prevalence of reduced kidney function (glomerular filtration rate, GFR <60 mL/min per 1.73 m 2 ). 6 In contrast, large datasets from general practices in Australia have not previously been used, although the country now seems well suited to such an approach. While laboratories in only 18% and 8% of countries report routine estimates of and proteinuria measures, respectively, 7 to assist in the recognition of CKD, Australian general practitioner (GP) have had access to routine GFR estimates for 10 years. 8 On average, 85% of Australians visit their general practitioner at least once in a year. 9 The details of these visits will typically be recorded electronically; by 2014 Australian GP were using EHR 98% of the time for prescribing and 70% reported a paperless office. 9 Paper-based GP recording of consultation details, using relatively small patient populations, has been previously used to extrapolate the prevalence of chronic conditions and multi-morbidity. 10 While the collection of cross-sectional de-identified data from Australian general practice EHR has been described, most studies to date have also used relatively small populations or been limited geographically.
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The National Prescribing Service (NPS) MedicineWise MedicineInsight dataset is the largest and most representative general practice/primary care clinical dataset yet developed in Australia 12, 13 ; it currently has over 650 recruited general practices, providing a database of over 3.6 million records of Australian patients. Since 2013, general practices and GP across Australia have been able to contribute their data. The dataset includes information from codable and free-text fields within an EHR, such as medication prescribed and vaccines given, biometrics, investigations ordered and conditions managed for each patient. Updating the data every 2-4 weeks provides a longitudinal picture for each person in the database 13 .
This study aimed to describe a large cohort of Australian general practice-based patients identified as having CKD, utilizing data from NPS MedicineWise's MedicineInsight dataset, and to compare this dataset against the ABS's CKD prevalence estimates. 4 The MedicineInsight dataset was also used to describe associated sociodemographic characteristics and comorbidities for Australians with CKD.
METHODS
The NPS MedicineWise's MedicineInsight data has been described elsewhere. 12 This dataset was collected from 329 participating practices representing 1 483 416 active patients from 1st June 2013 until 30th June 2016. Active patients are defined as those visiting the general practice at least three times over the previous 2 years. 14 We used two methods to calculate the prevalence of CKD in our population.
In the first method, data collected from 01 January 2013 to 01 June 2016 was used to identify patients ≥18 years of age with probable CKD stages 1-5. 15 All staging was based on estimated glomerular filtration rate (eGFR) and/or urinary albumin-to-creatinine ratio (ACR) results, as per the ABS's CKD criteria. 4 . We used each patient's first eGFR and first ACR in each calendar year to determine their stage of CKD, as per the Australian Health Survey (AHS). 3 Patients were only included in the dataset by the 30th
of June in the nominated year if they had a general practice encounter or a pathology result within the previous year.
In the second method, CKD status was determined by two eGFR results <60 mL/min per 1.73 m 2 at least 90 days apart, and/or presence of albuminuria for >90 days of ≥3.5 mg/mmol for females, and ≥2.5 mg/mmol for males.
We have labelled this cohort as 'Two eGFRs or ACRs CKD'. This method matches that recommended for the diagnosis of CKD in Australian general practice. 16 Both CKD cohorts were determined using pre-calculated eGFR measurement results routinely sent to general practices as part of a pathology dataset. The modification of diet in renal disease (MDRD) equation had been used to calculate the eGFR in 85% of the pre-calculated eGFR results, while the remainder were based on the chronic kidney disease epidemiology collaboration (CKD-Epi) equation. To standardize the mix of MDRD and CKD-EPI calculations of raw data eGFR, all eGFR were recalculated using the CKD-EPI (2009) formula. 17 As data had been obtained in 5 years age groups from NPS MedicineWise MedicineInsight, the patient's age at the time of testing was calculated as the median age of their respective 5 years group minus the number of days prior to the end of the study period that the test results were provided. ACR measurements were a stand-alone pathology request. The diagnoses of anxiety disorder, atrial fibrillation (AF), cardiovascular disease (CVD), CKD, diabetes mellitus (diabetes) and hypertension (HT) were recorded based on 'condition flags' provided by NPS MedicineWise MedicineInsight. Condition flags are devised using algorithms that analyse coded and free-text information in the fields of either 'encounter_reason', 'prescription_reason', or 'diagnosis_reason', 18, 19 .
Statistical analysis
All data cleaning, data manipulation and statistical analysis were completed using the statistical and graphical computing language of R (https://www.R-project.org/). Pearson's χ 2 test of independence was used to determine differences in proportions between the CKD cohort and all active patients in the dataset. Age-sex adjustment of raw prevalence rates, and their 95% confidence intervals (CI), were completed using the 'Age-standardization -direct method' described by Boyle and Martin. 20 Potential clustering by practice was not accounted for in the calculation of the 95% CI. The reference population for age-sex standardization was from the Australian Demographic Statistics (June 2016) report from the Australian Bureau of Statistics. 21 Rurality was based on Australian Bureau of Statistics' (ABS) Australian Statistical Geography Standard (ASGS) remoteness areas. 22 Socio-economic index was also based on patient postcode, using the socio-economic indexes for area (SEIFA) of relative socio-economic advantage and disadvantage decile. SEIFA is ranked from 1 (most disadvantaged area) to 10 (most advantaged) 23 .
RESULTS
The number of active patients varied over the three annual periods from 1 041 529 to 1 310 602, reflecting the increasing enrolment of general practices in the NPS MedicineWise MedicineInsight program over that period. As noted in Table 1 , while the number of patients in the dataset grew each year from 2014 to 2016 the percentage of patients not tested with either a measure of eGFR or ACR, those who were tested but did not meet AHS criteria for CKD, and those who met criteria for CKD 1-5 remained relatively stable. Table 2 describes the unadjusted prevalence of CKD for adult males and females, in 10 years age groupings in the year from 02 June 2015 to 01 June 2016. This year was the latest in the dataset. In Table 1 , three annual time-periods from June 2nd to June 1st each year (2014-2016) were used to compare the age-and sex-adjusted prevalence for each CKD stage with the figures obtained from the AHS in 2011-2012.
3 Figure 1 demonstrates the selection process leading to the more rigorous definition of CKD. 16 Each group with eGFR measures were then age-and sexadjusted against ABS data. Figure 2 is a Venn diagram illustrating the mix of comorbidities in patients from the 'Two eGFRs and/or 2 ACRs CKD' cohort.
DISCUSSION
The NPS MedicineWise MedicineInsight database provides a new tool for measuring the prevalence of CKD in the Australian population. Because the data is longitudinal with multiple pathology results per patient, it is possible to be more rigorous in defining a cohort of patients with CKD based on the requirement to more properly define CKD as having eGFR that remain at or below cut-off points over a period of 90 days or more. 16 The resultant large cohort is then useful to view as a more specific group with which to investigate factors leading to disease stability or progression. This could form an important CKD research tool and offers the same benefits as a registry but across earlier stages of CKD.
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The age-and sex-adjusted prevalence rates with the MedicineInsight dataset compare favourably with AHS figures for CKD stages 3a to 4-5, while figures for CKD 1-2 show a lower prevalence compared to AHS data. 3 This is likely to reflect the reasons for ordering pathology tests in general practice. Patients who may be diagnosable as CKD 1-2 may be comparatively well, presenting less often to their GP and having fewer reasons to have an eGFR and/or ACR ordered, while those with, for example, cardiovascular disease and diabetes are likely to have their renal function monitored regularly as part of overall management. 16 The MedicineInsight dataset showed a higher prevalence of CKD in Aboriginal and Torres Strait Islander (ATSI) populations (5.51%) than non-ATSI populations (4.22%). There was also a clear correlation between CKD prevalence and areas of socio-economic disadvantage, with prevalence increasing from 3.54% in the most advantaged quintile to 4.63% in the most disadvantaged quintile. These findings are consistent with patterns of CKD prevalence reported in the AHS. 1 The AHS dataset has limitations, noting that the current sample is dated -have been collected in 2011-2012, and is based on a relatively small sample, with the data based on 10 391 of 27 636 Australians over the age of 12 years submitting to one estimate of their eGFR, and 11 267 of 30 329 over the age of 5 years submitting a urine sample for an ACR.
3 Although the AHS results were then weighted against population benchmarks chosen to reduce random and systematic errors, the judicious use of the NPS MedicineWise MedicineInsight dataset could form a very useful adjunct noting the benefits of being drawn from a large, well-distributed population of Australians, its timeliness and associated extra data such as comorbidity prevalence. The finding that 88% of patients in the 'current' cohort had a GP encounter or pathology result during the period 02 June 2015 until 01 June 2016 (denoted as 2016) fits well with estimates that, on average, 85% of Australians visit their GP annually. 9 The higher percentage of patients with flagged conditions within the 'current' 2016 cohort reflects the expected higher engagement rates of these patients with their general practice. Hence, over a year 95.2% of patients with AF, 92.1% with anxiety disorder, 94.9% with CVD, 94.7% with diabetes, 94.9% with HT and 97.1% with CKD saw their GP or had recorded in their EHR a pathology result.
Age-and sex-adjusted MedicineInsight data suggests 40-45% of Australian patients had an eGFR estimate in 2016. We do not know why these tests were undertaken but, appropriately, patients with a diagnosis of CKD had an eGFR at an annual rate of 87.3%, those with diabetes 67.7%, with CVD 58.8%, HT 58.4%, and AF 57.5%. Those with anxiety disorder, as an example of a disorder not noted as a CKD comorbidity, were only a little above the 40-45% rate at 49.6%. This suggests GP and their patients were aware of a need to check renal function in the face of known CKD or comorbidities of highest risk for the development, or progression of CKD. The comorbidities of CKD patients managed by GP may be concordant conditions overlapping in pathophysiology and treatment goals such as HT and diabetes, or discordant with opposing management plans that may exacerbate CKD, such as arthritis and the use of non-steroidal antiinflammatory drugs. 25 Further exploration of this dataset to investigate the use of medications in the management of concordant and non-concordant conditions is planned. The NPS MedicineWise MedicineInsight dataset also has inherent limitations relating to its reliance on complete and accurate recording of data by GP, and the use of 'condition flags'. These limitations were partly illustrated by the finding that less than 25% of the patient with potentially diagnosable CKD had CKD documented as a 'condition flag' in their EHR. Comorbidities were recorded based on 'condition flags' provided by MedicineInsight, using an algorithm that analyses coded and free-text patient information; this algorithm has not been validated. Other limitations were the absence of 'condition flags' for haematuria, previous acute kidney injury, glomerulonephritis, or current renal replacement therapy, all factors of interest in describing the Australian population's CKD epidemiology.
Despite its limitations, the NPS MedicineWise MedicineInsight dataset could meet the call by researchers for the use of aggregated EHR data to evaluate primary care interventions, 26 while contributing to data-linkage studies that inform community-based needs assessment 27 and to drug post-marketing sentinel systems. 28 In the area of Australian patients with CKD, it is likely to provide a more valid source of information for pre-dialysis patients than current registries. 24 The relatively large group of patients comprising those with CKD stages 1-3 disease, as is compatible with guideline care, are managed by their general practice team. 16 It is likely the analysis of this dataset will assist the specialty of general practice to optimize the prevention of CKD and care of patients with CKD.
